Watchful of summer Covid-19 resurgence, Korea urges older adults to get vaccinated
Head of the Central Disaster and Safety Countermeasures Headquarters, Lee Han-kyung, visits a clinic in Cheongju, North Chungcheong Province, and inspects hospital beds on Monday (May 26, 2025). - Photo: Yonhap
SEOUL: The South Korean government is closely monitoring Covid-19 resurgences in regional neighbors including Hong Kong, China and Thailand, amid growing worries that a summer resurgence may hit the country again this year.
At a Central Disaster and Safety Countermeasures Headquarters meeting Friday (May 30), Director Lee Han-kyung warned of worsening Covid-19 trends abroad.
"In regions close to us — Hong Kong, China and Thailand — Covid-19 infections are rising, and this is a cause for concern," Lee said at the meeting.
He urged senior citizens aged 65 and above, as well as residents in high-risk facilities, to get vaccinated, stressing that vaccination is key to preventing severe illness and death.
According to government data, recent overseas Covid-19 cases are showing a noticeable uptick.
In Hong Kong, confirmed cases for the week of May 11 to 17 totalled 977, exceeding the country's previous summer peak of 796.
China's rate of positivity Covid-19 test results is steadily climbing toward last year's peak of 21.1 percent, while in Thailand, more than 65,000 new cases were reported in the three weeks following the Songkran holiday in April.
Despite the global trend, the number of new Covid-19 cases in Korea remained at around 100 each week over the past month.
Currently, South Korea estimates the number of confirmed cases in select hospitals on a weekly basis.
Still, the government is taking a proactive stance in consideration that domestic cases last year surged sharply from late July to mid-August.
Weekly confirmed cases jumped from 456 in the fourth week of July to over 1,400 by mid-August in 2023.
To mitigate potential risks, health authorities have extended the vaccination period for high-risk groups until June 30, two months beyond the initial April 30 deadline.
The Korean Medical Association also issued a public advisory, pointing to the seasonal temperature shifts, increased domestic and international travel and a noticeable drop in personal hygiene practices such as hand-washing.
It recommended six precautionary measures: maintaining personal hygiene, wearing masks, prompt response to symptoms, testing for high-risk individuals and recent international travellers, getting vaccinated and improving indoor ventilation.
Recalling difficulties caused by last summer's surge, the association emphasised that preventive habits such as hand-washing and mask-wearing remain crucial. - The Korea Herald/ANN
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Rakyat Post
15 hours ago
- Rakyat Post
Malaysia Records First COVID-19 Death In 2025
Subscribe to our FREE Malaysia has recorded its first COVID-19-related death of 2025, according to a statement released by the Ministry of Health (MoH) on 19 June. The fatality occurred during Epidemiological Week 24 (8–15 June). The individual, who had serious pre-existing health conditions such as heart disease and diabetes, had not received the second booster dose of the COVID-19 vaccine. MoH noted that this was the first COVID-19 death since 26 May 2024, and a significant drop compared to the 57 COVID-related deaths reported in 2024. COVID-19 Cases on the Rise, But Situation Under Control As of Week 24, Malaysia has reported 21,738 cumulative COVID-19 cases in 2025, with the weekly average hovering around 900 cases. However, MoH did flag a 68% week-on-week spike, with 3,379 cases reported in Week 24 compared to 2,011 the previous week. Despite the increase, the ministry assured that the national COVID-19 situation remains stable and below the national alert threshold. In terms of severe cases, six patients were admitted to the ICU, all with underlying health issues. All have since been discharged from intensive care; four have returned home, while two remain in regular hospital wards for follow-up treatment. New Variant on the Radar: NB.1.8.1 or 'Nimbus' The World Health Organisation (WHO) is closely monitoring the spread of NB.1.8.1, a Photo: Freepik WHO has classified Nimbus as a Variant Under Monitoring (VUM) due to its rapid transmission and potential health risks. Nimbus spreads faster than previous variants. Common symptoms include: razor-blade-like sore throat, fatigue, mild cough, fever, muscle aches and nasal congestion. What You Can Do Health experts continue to urge the public to take precautions, especially as new variants emerge. Wear a high-quality mask in crowded indoor spaces, improve indoor ventilation: open windows, use fans or air purifiers, get tested if you're feeling unwell or exposed to COVID-19, and stay home when sick to reduce the risk of transmission. Photo: Malay Mail While Malaysia's current COVID-19 situation remains under control, this latest death and the emergence of new variants serve as reminders that vigilance and public health measures remain crucial. Share your thoughts with us via TRP's . Get more stories like this to your inbox by signing up for our newsletter.
New Straits Times
15 hours ago
- New Straits Times
Safeguards critical in tapping EPF savings for private healthcare, says expert
KUALA LUMPUR: A bold plan to allow Malaysians to tap into their Employees Provident Fund (EPF) Account 2 to pay for health insurance may help ease access to private healthcare. However, an analyst cautions that without careful safeguards, it could leave retirees vulnerable later in life. The proposal, which aims to address rising healthcare costs and access concerns, is a potentially meaningful step, particularly for middle-income earners and the ageing population, who are often excluded from targeted public health aid. Universiti Putra Malaysia School of Business and Economics lecturer Associate Professor Dr Lee Chin said that while the initiative fills a gap in health protection, the long-term implications for retirement adequacy must not be overlooked. "From a social protection standpoint, enabling the use of EPF savings for health insurance could fill an important gap, especially for the ageing population and middle-income groups who fall outside public safety nets. However, contributors must be well-informed. "Account 2 was designed to support housing, education and emergencies — all of which are already pressing needs. Allowing health insurance payments from the same source adds another layer of pressure," she told the New Straits Times. Lee added that without proper caps or financial literacy support, contributors risk depleting their savings too quickly, leaving little for their retirement years. From a broader policy perspective, she said such flexibility should be paired with strong public education campaigns to help contributors make informed decisions, alongside safeguards to ensure withdrawals are responsibly managed. "At the same time, the move could have ripple effects on the health insurance sector. By enabling more people — particularly those previously uninsured — to afford private coverage, the insurance pool could grow, improving risk distribution and potentially lowering premium costs over time." However, she cautioned that a sudden spike in demand could also lead to higher premiums or moral hazard without sufficient regulatory oversight. "Insurers and regulators must be prepared to monitor cost escalation and prevent abuse," she said. As for fund sustainability, Lee said that while Account 1 remains ring-fenced for retirement, even partial erosion of Account 2 could undermine long-term financial resilience, particularly among lower to middle-income groups. She cited examples such as Singapore's MediSave and Chile's pension-linked health models, which allow similar withdrawals under strict regulatory frameworks, often supported by employer or government co-payments. "Malaysia can learn from these examples to design a scheme that is targeted, transparent and accountable." She added that the policy could serve as a much-needed bridge between financial and health protection, provided it is not treated as a short-term fix. "In short, this policy could bridge the gap between financial security and health protection —but only if it walks the line carefully. Health access should not come at the cost of growing old in hardship." On June 19, Health Minister Datuk Seri Dr Dzulkefly Ahmad said the government was considering allowing EPF members to use their Account 2 savings to pay for monthly health insurance premiums. He said that, if implemented, the initiative could enable 16 million EPF contributors to access private hospital treatment using their contributions. However, Dzulkefly later clarified that the proposed health insurance scheme — funded through EPF Account 2 — would be voluntary and not mandatory.
